SCHEMBL24320131

SCHEMBL24320131

Nc1ccc(Br)cc1C(=O)Nc1ccccn1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 1/20 0.71
NPC1 O15118 6/20 0.55
RAB9A P51151 6/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
KDM4E B2RXH2 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
GCK P35557 1/20 0.54
GRM5 P41594 2/20 0.53
TP53 P04637 3/20 0.52
ALDH1A1 P00352 1/20 0.52
POLB P06746 2/20 0.52
GLA P06280 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
CHRNB2 P17787 1/20 0.51
CHRNB4 P30926 1/20 0.51
CHRNA3 P32297 1/20 0.51
CHRNA4 P43681 1/20 0.51
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29980979 0.83 SORT1 (1.00) SORT1NPC1RAB9AMEN1KMT2A
SCHEMBL20610060 0.83 SORT1 (0.71) SORT1NPC1RAB9AMEN1KMT2A
SCHEMBL30417156 0.83 SORT1 (0.71) SORT1NPC1RAB9AMEN1KMT2A
SCHEMBL15903084 0.83 SORT1 (1.00) SORT1NPC1RAB9AMEN1KMT2A
SCHEMBL3151420 0.83 KCNMA1 (0.73) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL15903086 0.83 SORT1 (0.90) SORT1NPC1RAB9AMEN1KMT2A
SCHEMBL1961500 0.82 MEN1 (0.69) SORT1NPC1RAB9AMEN1KMT2A
SCHEMBL30339171 0.82 MEN1 (0.69) SORT1NPC1RAB9AMEN1KMT2A
SCHEMBL29111583 0.82 SORT1 (0.65) SORT1NPC1RAB9AMEN1KMT2A
SCHEMBL30516958 0.82 SORT1 (0.65) SORT1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240034723-A1 PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-02-01 US disclosed
CN-116669769-A Piperidinyl small molecule degradants of HELIOS and methods of use 达纳-法伯癌症研究所公司 2023-08-29 CN disclosed
EP-4228651-A1 PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE Dana-Farber Cancer Institute, Inc. (US) 2023-08-23 EP disclosed
WO-2022081976-A1 PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-21 WO disclosed
WO-2022081976-A1 PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034723-A1 PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE IKZF2, IKZF1, NUTF2 SORT1 4278/4885NPC1 2342/4885RAB9A 4461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.